- Home
- FRBT vs QURE Comparison
FRBT vs QURE Comparison
Compare FRBT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBT | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.8M | 1.1B |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FRBT | QURE |
|---|---|---|
| Price | $19.08 | $40.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 112.5K | ★ 1.4M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.72 | $8.73 |
| 52 Week High | $22.00 | $71.50 |
Technical Indicators
Market Signals| Indicator | FRBT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 49.10 |
| Support Level | $18.29 | $21.16 |
| Resistance Level | $21.22 | $50.47 |
| Average True Range (ATR) | 1.45 | 2.28 |
| MACD | -0.05 | -0.88 |
| Stochastic Oscillator | 15.63 | 37.75 |
Price Performance
Historical ComparisonAbout FRBT Forbright Inc. Class A Common Stock
Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.